Translational Therapeutics
British Journal of Cancer (2005) 92, 290–293. doi:10.1038/sj.bjc.6602329 www.bjcancer.com
Published online 11 January 2005
The human papillomavirus E6 and E7 inducible oncogene, hWAPL, exhibits potential as a therapeutic target
M Kuroda1,2,3,5, T Kiyono4,5, K Oikawa1,2,3,5, K Yoshida1,3 and K Mukai1
- 1Department of Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan
- 2CREST Research Project, Japan Science and Technology Corporation, Kawaguchi-shi, Saitama 332-0012, Japan
- 3Shinanomachi Research Park, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan
- 4Division of Virology, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan
Correspondence: Dr M Kuroda, Department of Pathology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. E-mail: kuroda@tokyo-med.ac.jp
5These authors contributed equally
Received 31 August 2004; Revised 12 October 2004; Accepted 15 October 2004; Published online 11 January 2005.
Abstract
Here we show that human papillomavirus (HPV) E6 and E7 oncoproteins induce hWAPL expression. In addition, small interfering RNA (siRNA) of hWAPL suppressed the growth of tumours derived from SiHa cells in nude mice. Thus, hWAPL may be one of the effective targets of uterine cervical cancer therapy.
Keywords:
hWAPL, HPV, E6, E7, siRNA
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Journal of Cerebral Blood Flow & Metabolism Original Article
Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells
Oncogene Original Article
Cancer Gene Therapy Original Article
Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21 CIP -dependent pathways
The EMBO Journal Article (01 Nov 2000)
